Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
Ohio State University Comprehensive Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
Emory University
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
City of Hope Medical Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
OHSU Knight Cancer Institute